Ya'NAn Chen

Ya'NAn Chen

Auto-generated profile, based on publicly available information

Ya'NAn Chen

Department of Pharmacy Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University Nanjing China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2025 in Current Computer-Aided Drug Design
Verified
Journal Article
Closed access
PDF file
YCYa'NAn Chen
Ya'NAn Chen
JZJingkai Zhou
Jingkai Zhou
SXShansen Xu
Shansen Xu
LWLei Wang
Lei Wang
Background: Valproic acid (VPA)-induced hepatotoxicity is among the most common and severe adverse drug reactions, limiting its clinical application. Recent studies have suggested that activating the farnesoid X receptor (FXR) could be a promising therapeutic approach to alleviate VPA-induced hepatotoxicity; however, related research remains limited. Objective: This study aims to comprehensively investigate the mechanisms underlying FXR activation by obeticholic acid (OCA) for the treatment of VPA-induced hepatotoxicity. Methods: Network pharmacology was performed to identify potential targets and pathways underlying the amelioration of VPA-induced hepatotoxicity by OCA. The identified pathways were validated through GEO data analysis, and the affinities between OCA and potential key targets were predicted using molecular docking as well as molecular dynamics simulations. Results: A total of 462 targets associated with VPA-induced hepatotoxicity and 288 targets of OCA were identified, with 81 shared targets. KEGG pathway and GO enrichment analysis indicated that the effect of OCA on VPA-induced hepatotoxicity primarily involved lipid metabolism, as well as oxidative stress and inflammation. The results from GEO data analysis, molecular docking, and molecular dynamics simulations revealed a close association between bile secretion, the PPAR signaling pathway, and the treatment of VPA-induced hepatotoxicity by OCA. Conclusion: Our findings suggest that OCA exhibits potential therapeutic efficacy against VPAinduced hepatotoxicity through multiple targets and pathways, thereby highlighting the therapeutic potential of FXR as a target for treating VPA-induced hepatotoxicity.

4 November 2025 in Lipids
Verified
Journal Article
Closed access
SXShansen Xu
Shansen Xu
XMXianglei Ma
Xianglei Ma
LHLingli Huang
Lingli Huang
TYTingting Yue
Tingting Yue
YCYa'NAn Chen
Ya'NAn Chen

16 November 2025 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Closed access
TYTingting Yue
Tingting Yue
LZLimei Zhao
Limei Zhao
YCYa'NAn Chen
Ya'NAn Chen
SXShansen Xu
Shansen Xu